Journal of Gastroenterology

, Volume 46, Issue 11, pp 1300–1306 | Cite as

Platelet count for predicting fibrosis in nonalcoholic fatty liver disease

  • Masato Yoneda
  • Hideki Fujii
  • Yoshio Sumida
  • Hideyuki Hyogo
  • Yoshito Itoh
  • Masafumi Ono
  • Yuichiro Eguchi
  • Yasuaki Suzuki
  • Noriaki Aoki
  • Kazuyuki Kanemasa
  • Kento Imajo
  • Kazuaki Chayama
  • Toshiji Saibara
  • Norifumi Kawada
  • Kazuma Fujimoto
  • Yutaka Kohgo
  • Toshikazu Yoshikawa
  • Takeshi Okanoue
  • Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

The severity of liver fibrosis is known to be a good indicator for surveillance, and for determining the prognosis and optimal treatment of nonalcoholic fatty liver disease (NAFLD). However, it is virtually impossible to carry out liver biopsies in all NAFLD patients. The purpose of this study was to investigate the clinical usefulness of measuring the platelet count for predicting the severity of liver fibrosis in a large retrospective cohort of Japanese patients with NAFLD.

Methods

A total of 1,048 patients with liver-biopsy-confirmed NAFLD seen between 2002 and 2008 were enrolled from nine hepatology centers in Japan. Laboratory evaluations were performed for all patients.

Results

A linear decrease of the platelet count with increasing histological severity of hepatic fibrosis was revealed. The area under the receiver operating characteristic curve estimating the diagnostic performance of the platelet count for hepatic fibrosis Stage 3 was 0.774 (optimal cutoff value, 19.2 × 104/μl; sensitivity, 62.7%; specificity, 76.3%), and that for Stage 4 was 0.918 (optimal cutoff value, 15.3 × 104/μl; sensitivity, 80.5%; specificity, 88.8%).

Conclusions

The platelet count may be an ideal biomarker of the severity of fibrosis in NAFLD patients, because it is simple, easy to measure and handle, cost-effective, and accurate for predicting the severity of fibrosis. Furthermore, by using the platelet count cutoff value validated in our multiple large trials, efficient recruitment of NAFLD patients may be facilitated.

Keywords

Nonalcoholic fatty liver disease Platelet Fibrosis 

Abbreviations

NAFLD

Nonalcoholic fatty liver disease

AST

Aspartate aminotransferase

ALT

Alanine aminotransferase

AUROC

Area under the receiver operating characteristic

BMI

Body mass index

APRI

Aspartate aminotransferase to platelet ratio index

References

  1. 1.
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;18:1221–31.CrossRefGoogle Scholar
  2. 2.
    Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol. 2006;40(Suppl 1):S11–6.PubMedGoogle Scholar
  3. 3.
    National Institutes of Health. National Institutes of Health Consensus Development Conference statement: management of hepatitis C 2002 (June 10–12, 2002). Hepatology. 2002;36(5 Suppl 1):S3–20.Google Scholar
  4. 4.
    Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology. 1999;30:1356–62.PubMedCrossRefGoogle Scholar
  5. 5.
    Cadranel JF. Good clinical practice guidelines for fine needle aspiration biopsy of the liver: past, present and future. Gastroenterol Clin Biol. 2002;26:823–4.PubMedGoogle Scholar
  6. 6.
    Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology. 2001;33:196–200.PubMedCrossRefGoogle Scholar
  7. 7.
    Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol. 2003;14:543–8.Google Scholar
  8. 8.
    Saibara T. Nonalcoholic steatohepatitis in Asia-Oceania. Hepatol Res. 2005;33:64–7.PubMedCrossRefGoogle Scholar
  9. 9.
    Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet. 2003;362:2095–100.PubMedCrossRefGoogle Scholar
  10. 10.
    Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 1988;8:493–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat. 1997;4:199–208.PubMedCrossRefGoogle Scholar
  12. 12.
    Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518–26.PubMedCrossRefGoogle Scholar
  13. 13.
    Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54.PubMedCrossRefGoogle Scholar
  14. 14.
    Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, et al. A simple clinical scoring system using ferritin, fasting insulin and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46(2):257–68.PubMedCrossRefGoogle Scholar
  16. 16.
    Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705–25.PubMedCrossRefGoogle Scholar
  17. 17.
    Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Sanyal AJ, Brunt EM, Kleiner DE, Kowdley K, Chalasani N, Lavine J, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54(1):344–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol. 2010;16:5286–96.PubMedCrossRefGoogle Scholar
  20. 20.
    Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.PubMedCrossRefGoogle Scholar
  21. 21.
    Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol. 2004;2:1048–58.PubMedCrossRefGoogle Scholar
  22. 22.
    Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74–80.PubMedCrossRefGoogle Scholar
  23. 23.
    Kajihara M, Okazaki Y, Kato S, Ishii H, Kawakami Y, Ikeda Y, et al. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol. 2007;22:112–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Park KS, Lee YS, Park HW, Seo SH, Jang BG, Hwang JY, et al. Factors associated or related to with pathological severity of nonalcoholic fatty liver disease. Korean J Intern Med. 2004;19:19–26.PubMedGoogle Scholar
  25. 25.
    Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K. Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2006;21:1459–65.PubMedGoogle Scholar
  26. 26.
    Aster RH. Pooling of platelets in the splenic. J Clin Invest. 1966;45:645–57.PubMedCrossRefGoogle Scholar
  27. 27.
    Schmidt KG, Rasmussen JW, Bekker C, Madsen PE. Kinetics and in vivo distribution of 111-In-labelled autologous platelets in chronic hepatic disease: mechanisms of thrombocytopenia. Scand J Haematol. 1985;34:39–46.PubMedCrossRefGoogle Scholar
  28. 28.
    Nakamura S, Konishi H, Kishino M, Yatsuji S, Tokushige K, Hashimoto E, et al. Prevalence of esophagogastric varices in patients with non-alcoholic steatohepatitis. Hepatol Res. 2008;38:572–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Reynolds TB, Hidemura R, Michel H, Peters R. Portal hypertension without cirrhosis in alcoholic liver disease. Ann Intern Med. 1969;70:497–506.PubMedGoogle Scholar
  30. 30.
    Bolognesi M, Merkel C, Sacerdoti D. Role of spleen enlargement in cirrhosis with portal hypertension. Dig Liver Dis. 2002;34:144–50.PubMedCrossRefGoogle Scholar
  31. 31.
    Suzuki K, Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Nozaki Y, et al. Measurement of spleen volume is useful for distinguishing between simple steatosis and early-stage non-alcoholic steatohepatitis. Hepatology Res. 2010;40:693–700.CrossRefGoogle Scholar
  32. 32.
    Fujii H, Enomoto M, Fukushima W, Ohfuji S, Mori M, Kobayashi S, et al. Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol. 2009;44:608–814.PubMedCrossRefGoogle Scholar
  33. 33.
    Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–12.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Masato Yoneda
    • 1
  • Hideki Fujii
    • 2
  • Yoshio Sumida
    • 3
  • Hideyuki Hyogo
    • 4
  • Yoshito Itoh
    • 5
  • Masafumi Ono
    • 6
  • Yuichiro Eguchi
    • 7
  • Yasuaki Suzuki
    • 8
  • Noriaki Aoki
    • 9
  • Kazuyuki Kanemasa
    • 3
  • Kento Imajo
    • 1
  • Kazuaki Chayama
    • 4
  • Toshiji Saibara
    • 6
  • Norifumi Kawada
    • 2
  • Kazuma Fujimoto
    • 7
  • Yutaka Kohgo
    • 8
  • Toshikazu Yoshikawa
    • 5
  • Takeshi Okanoue
    • 10
  • Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)
  1. 1.Division of GastroenterologyYokohama City University Graduate School of MedicineYokohamaJapan
  2. 2.Department of Hepatology, Graduate School of MedicineOsaka City UniversityOsakaJapan
  3. 3.Center for Digestive and Liver DiseasesNara City HospitalNaraJapan
  4. 4.Department of Medicine and Molecular Science, Graduate School of Biomedical SciencesHiroshima UniversityHiroshimaJapan
  5. 5.Department of Gastroenterology and HepatologyKyoto Prefectural University of MedicineKyotoJapan
  6. 6.Department of Gastroenterology and HepatologyKochi Medical SchoolKochiJapan
  7. 7.Department of General MedicineSaga Medical SchoolSagaJapan
  8. 8.Division of Gastroenterology and Hematology/Oncology, Department of MedicineAsahikawa Medical CollegeAsahikawaJapan
  9. 9.School of Biomedical InformaticsUniversity of Texas Health Science Center at HoustonHoustonUSA
  10. 10.Hepatology CenterSaiseikai Suita HospitalSuitaJapan

Personalised recommendations